Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 May 3:38:102345.
doi: 10.1016/j.ajoc.2025.102345. eCollection 2025 Jun.

Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies

Affiliations
Case Reports

Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies

Tara Murty et al. Am J Ophthalmol Case Rep. .

Abstract

Purpose: To report two new cases and summarize one case of uveal melanoma following treatment of hematologic malignancies with Bruton's tyrosine kinase inhibitors.

Observations: A 71-year-old male, with a history of Waldenstrom macroglobulinemia treated with an anti-CD20 antibody and BTKi, was diagnosed with a choroidal melanoma with intraocular metastasis. A 73-year-old female, with a history of Mantle Cell Lymphoma treated with an alkylating chemotherapy and an anti-CD20 antibody, relapse, and subsequent treatment with BTKi, was diagnosed with a uveal melanoma.

Conclusions and importance: Patients being treated with BTK inhibitors may be at higher risk for the development of uveal melanoma. Based on our findings, we recommend increased surveillance of this patient population for secondary primary or metastatic uveal melanoma. Continued documentation of occurrence in conjunction with research at a molecular and cellular level are warranted to better understand the impact of systemic cancer therapies on secondary malignancies.

Keywords: Bruton's tyrosine kinase inhibitor; Hematologic malignancy; Uveal melanoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Imaging of a 71-year-old patient with a uveal melanoma of the left eye: (A) Slit lamp examination shows 3+ nuclear sclerotic cataract and a pigmented anterior iris lesion emanating from the iris root (black arrow). (B) 20 MHz B scan ultrasonography demonstrates a large anterior uveal melanoma apical thickness of 9.9 mm. (C) Ultrasound biomicroscopy demonstrates the anterior location of the tumor with ciliary body focus and iris root breakthrough.
Fig. 2
Fig. 2
Imaging of a 73-year-old patient with a uveal melanoma of the right eye: (A) Slit lamp examination shows dilated, tortuous sentinel scleral vessels inferotemporally (black arrow). (B) Ultrawidefield fundus photography demonstrates the large anteriorly placed choroidal mass (white arrow). (C) 20 MHz B scan ultrasonography demonstrates a large anterior uveal melanoma with apical thickness of 13.61 mm.

Similar articles

References

    1. Kaliki S., Shields C.L. Uveal melanoma: relatively rare but deadly cancer. Eye. 2017;31(2):241–257. doi: 10.1038/eye.2016.275. 312. 2016. - DOI - PMC - PubMed
    1. Metastatic uveal melanoma - UpToDate. https://www.uptodate.com/contents/metastatic-uveal-melanoma
    1. Initial management of uveal and conjunctival melanomas - UpToDate. https://www.uptodate.com/contents/initial-management-of-uveal-and-conjun...
    1. Shen Y., Coyle L., Kerridge I., et al. Second primary malignancies in chronic lymphocytic leukaemia: skin, solid organ, haematological and Richter's syndrome. eJHaem. 2022;3(1):129–138. doi: 10.1002/jha2.366. - DOI - PMC - PubMed
    1. Poh C., Keegan T., Rosenberg A.S. Second primary malignancies in multiple myeloma: a review. Blood Rev. 2021;46(September 2020) doi: 10.1016/j.blre.2020.100757. - DOI - PMC - PubMed

Publication types

LinkOut - more resources